INDSWFTLAB Intraday Analysis...

INDSWFTLAB Share Price

Open 36.00 Change Price %
High 37.85 1 Day 0.25 0.70
Low 35.75 1 Week -0.95 -2.57
Close 36.05 1 Month -1.00 -2.70
Volume 48139 1 Year -1.30 -3.48
52 Week High 52.80
52 Week Low 33.30
INDSWFTLAB Important Levels
Resistance 2 38.00
Resistance 1 37.19
Pivot 36.55
Support 1 34.91
Support 2 34.10
NSE INDIA Most Active Stocks
JPASSOCIAT 15.05 0.67%
GMRINFRA 15.45 7.67%
JINDALSTEL 100.15 7.69%
MARKSANS 48.60 20.00%
UNITECH 5.95 0.85%
RCOM 34.65 4.52%
IDEA 108.45 2.41%
FEDERALBNK 85.95 3.06%
SOUTHBANK 20.70 3.50%
JPPOWER 6.15 4.24%
More..
NSE INDIA Top Gainers Stocks
MARKSANS 48.60 20.00%
GOLDTECH 9.75 19.63%
PANACEABIO 158.35 19.33%
AUSTRAL 0.35 16.67%
IL&FSENGG 64.10 16.33%
DHARSUGAR 34.90 15.75%
UMANGDAIRY 84.45 14.59%
KAMATHOTEL 39.45 10.66%
VISASTEEL 22.45 10.59%
PEARLPOLY 30.45 10.53%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.10 -33.33%
VKSPL 0.10 -33.33%
HOTELRUGBY 4.00 -18.37%
LLOYDELENG 273.20 -16.59%
FCSSOFT 0.30 -14.29%
BLUECHIP 0.35 -12.50%
SRGINFOTEC 0.35 -12.50%
XLENERGY 2.85 -9.52%
ADHUNIK 7.85 -8.72%
GUJNREDVR 2.10 -8.70%
More..

Ind-Swift Laboratories Limited (NSE: INDSWFTLAB)

INDSWFTLAB Technical Analysis 4
As on 20th Feb 2017 INDSWFTLAB Share Price closed @ 36.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 39.42 & Sell for SHORT-TERM with Stoploss of 36.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
INDSWFTLAB Target for February
1st Target up-side 39.28
2nd Target up-side 40.85
3rd Target up-side 42.42
1st Target down-side 34.82
2nd Target down-side 33.25
3rd Target down-side 31.68
INDSWFTLAB Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
INDSWFTLAB Other Details
Segment EQ
Market Capital 872314432.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.indswiftlabs.com
INDSWFTLAB Address
INDSWFTLAB
Shivalik Enclave
SCO 850
Manimajra, 160101
India
Phone: 91 17 2273 0503
Fax: 91 17 2273 0504
INDSWFTLAB Latest News
Ind-Swift Labs To Raise Funds From Strategic Investors   DealCurry   - 31st Jul 14
Ind-Swift Lab extends Tuesday's rally   Business Standard   - 23rd Jul 14
SP Tulsian's multibaggers: Rallis India, Ind-Swift Labs   Moneycontrol.com   - 11th Jun 13
Ind-Swift Labs aims to touch Rs 1500cr turnover by 2015   Moneycontrol.com   - 09th Dec 12
Piramal Healthcare in talks to buy Ind-Swift Lab: Report   India Today   - 04th Sep 12
Ind-Swift Labs board approves debt recast plan   Hindu Business Line   - 16th Jul 12
Ind-Swift, Wockhardt launch Atorvastatin tablets in UK   Economic Times   - 16th May 12
Ind-Swift Labs gets USFDA approval for 5 APIs for its Derabassi facility   Moneylife Personal Finance site and magazine   - 10th Apr 12
Expect turnover of Rs 50cr from menthol biz: Ind-Swift Labs   Moneycontrol.com   - 26th Dec 11
Ind-Swift Labs eyes good volumes on exports to Japan   Moneycontrol.com   - 18th Feb 11
Interactive Technical Analysis Chart Ind-Swift Laboratories Limited ( INDSWFTLAB NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ind-Swift Laboratories Limited
INDSWFTLAB Business Profile
Ind-Swift is in the Pharmaceuticals - Bulk Drugs sector. Incorporated in 1995, Chandigarh, India-based Ind-Swift Laboratories (ISL) is a part of the Ind-Swift group. The company is promoted and managed by Ind-Swift in joint venture with Punjab State Industrial Development Corporation. Manufacturing units of ISL are located in Punjab and Jammu. Ind Swift Laboratories, a wholly owned subsidiary of ISL, was incorporated in the USA in Mar. 2004. It manufactures a wide range of solid, liquid, semi liquid forms, capsule, tablets, dry/liquid injectable eye/ear drops, oral solution, and creams/gels. The company`s products include Clarithromycin, Fexofenadine, Clarie granules, Pentazocine, Roxithromycin, Clopidogrel, Azithromycin, and Atorvastatin. Its products are used in the macrolide antibiotic, antiallergy, cardiovascular, diabetology, and antiulcerant therapeutic sector. ISL has emerged as an efficient supplier of bulk-actives in more than 45 countries. The services of the company includes research for active pharmaceuticals intermediaries / advanced intermediates, development of non-infringing processes for promising molecules, process optimization and improvement, contract research, contract manufacturing, etc. The current market capitalisation stands at Rs 28.58 crore.The company has reported a standalone sales of Rs 139.17 crore and a Net Loss of Rs 41.99 crore for the quarter ended Jun 2013. The company management includes S R Mehta - Chairman, N R Munjal - Vice Chairman, Gopal Munjal - Managing Director & CEO, V R Mehta - Joint Managing Director, Himanshu Jain - Director, Rishav Mehta - Director, K M S Nambiar - Director, R S Bedi - Director, H P S Chawla - Director, S K Mathur - Director, S P Sharma - Independent Director, Atul Saxena - Nominee Director. It is listed on the BSE with a BSE Code of 524652 and the NSE with an NSE Code of INDSWFTLTD. Its Registered office is at 781, Industrial Area - II , Chandigarh,Chandigarh - 160002.